In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston.
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.
C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.
In this week's podcast edition of Five Must-Know Things: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity.
Thanks in part to its HIV focus, Gilead was an early adopter when it came to emphasizing diversity in trials.
With ten years of experience at Roche under his belt, ten23 CEO and co-founder talked to Scrip about trends in the Swiss manufacturing landscape, from pandemic-related capacity growth to increased demand for small-batch production and sustainability efforts.
Via a partnership with Vanguard Renewables, AstraZeneca is converting its US locations to renewable natural gas, part of a goal to achieve net zero for carbon emissions by 2045.
The Foundation for Sarcoidosis Research briefed US Congress on participation by Black patients in sarcoidosis and other rare disease trials. Also, the US FDA issued a draft guidance on psychedelic drug trials; Insilico is taking its AI-discovered IPF drug into Phase II; and Compugen and Jasper dosed patients in their oncology trials.
In this new feature, Scrip's APAC team selects some notable quotes from recent interviews, conferences and other coverage.
Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
In this week's podcast edition of Five Must-Know Things: J&J’s Duarto on the importance of diversity; Teva’s views on its new risperidone launch; Almirall’s hopes for lebrikizumab; Biogen’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.